SCHEMBL6484162

SCHEMBL6484162

OC/C=C/c1ccc(-c2cc(Cl)cc(Cl)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ AHR P35869 3/20 0.44
▸ RXRA P19793 1/20 0.43
▸ RXRB P28702 1/20 0.43
▸ HDAC2 Q92769 3/20 0.39
▸ CHKA P35790 1/20 0.39
▸ S1PR1 P21453 1/20 0.36
▸ S1PR5 Q9H228 1/20 0.36
▸ CYP1A2 P05177 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ GRIK1 P39086 1/20 0.34
▸ GRIK2 Q13002 1/20 0.34
▸ ALOX5 P09917 1/20 0.33
▸ PTGS1 P23219 1/20 0.33
▸ PTGS2 P35354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6484173 1.00 ALDH1A1 (0.47) ALDH1A1CYP3A4RECQLAHRRXRA
SCHEMBL79527 0.80 ALDH1A1 (0.52) ALDH1A1CYP3A4RECQLAHRHDAC2
SCHEMBL79528 0.80 ALDH1A1 (0.52) ALDH1A1CYP3A4RECQLAHRHDAC2
SCHEMBL9276381 0.77 ALDH1A1 (0.62) ALDH1A1CYP3A4RECQLCYP1A2HSD17B10
SCHEMBL9276383 0.77 ALDH1A1 (0.62) ALDH1A1CYP3A4RECQLCYP1A2HSD17B10
SCHEMBL5580490 0.76 MGLL (0.53) ALDH1A1CYP3A4RECQLHDAC2GRIK1
SCHEMBL14984804 0.76 ALDH1A1 (0.53) ALDH1A1CYP3A4RECQLHDAC2CYP1A2
SCHEMBL5580493 0.76 MGLL (0.53) ALDH1A1CYP3A4RECQLHDAC2GRIK1
SCHEMBL28437771 0.75 PTGS1 (0.49) ALDH1A1CYP3A4RECQLCYP1A2ALOX5
SCHEMBL28437772 0.75 PTGS1 (0.49) ALDH1A1CYP3A4RECQLCYP1A2ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6867218-B2 Compounds, their preparation and use NOVO NORDISK A/S (DK) 2005-03-15 — — US disclosed
US-20030195200-A1 Compounds, their preparation and use VTVX HOLDINGS II LLC 2003-10-16 — — US disclosed
US-6555577-B1 For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example NOVO NORDISK A/S (DE) 2003-04-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195200-A1 Compounds, their preparation and use PPARG, PPARA, PPARD ALDH1A1 257/4885CYP3A4 540/4885RECQL 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback